Lantern Pharma
LTRN
33 hedge funds and large institutions have $13.1M invested in Lantern Pharma in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 3 reducing their positions, and 5 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 3
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
32% more funds holding
Funds holding: 25 → 33 (+8)
2.28% more ownership
Funds ownership: 12.53% → 14.81% (+2.3%)
16% less capital invested
Capital invested by funds: $15.7M → $13.1M (-$2.54M)
98% less call options, than puts
Call options by funds: $2K | Put options by funds: $122K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$3.07M |
| 2 |
CC
Carlson Capital
Dallas,
Texas
|
+$1.14M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$894K |
| 4 |
Two Sigma Investments
New York
|
+$636K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$594K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$7M |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$289K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$51.1K |
| 4 |
US Bancorp
Minneapolis,
Minnesota
|
-$22K |
| 5 |
WWM
Wolff Wiese Magana
Carslbad,
California
|
-$10.8K |
LTRN Hedge Fund Activity: Q4 2021 in Review
33 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q4 2021, worth a combined $13.1M — down 16% from $15.7M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new LTRN positions and 5 closed out — a net gain of 8 holders — while 12 added to existing stakes and 3 trimmed.
The largest buyer was Sanders Morris Harris, opening a new position worth an estimated $3.07M. The largest seller was Corriente Advisors, exiting entirely with an estimated $7M sold.
- 33 institutional investors held Lantern Pharma (LTRN) as of Q4 2021, up from 25 in Q3 2021.
- Funds reported $13.1M of Lantern Pharma stock for Q4 2021, down 16% quarter-over-quarter.
- 13 funds opened new Lantern Pharma positions in Q4 2021 and 5 closed out, a net change of +8 holders.
- The largest Lantern Pharma buyer in Q4 2021 was Sanders Morris Harris, an estimated $3.07M added.
- The largest Lantern Pharma seller in Q4 2021 was Corriente Advisors, an estimated $7M sold.
Based on aggregated 13F filings for Q4 2021.